Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Stephen Finn

Associate Professor Consultant (Histopathology)
      
Profile Photo

Dr. Stephen Finn

Associate Professor Consultant (Histopathology)

 Stephen.Finn@tcd.ie

 


Dr. Stephen Finn MB BAO BCh FDS PhD FRCPath FFPATH, is an Associate Professor, Consultant Pathologist and Principal Investigator at The University of Dublin, Trinity College and at St. James's Hospital Dublin, a tertiary referral cancer institution. He is Clincial Lead for Solid Tumour Molecular Diagnostics and co-director of the Cancer Molecular Diagnostic Laboratory. His clinical practice is limited to Molecular, Urological, Gastrointestinal and Liver pathology. Dr. Finn is former Senior Scientist and Staff Pathologist to the Centre for Molecular Oncologic Pathology at the Dana Farber Cancer Institute, Boston, USA. Dr. Finn continues to have strong personal and collaborative links to the Harvard School of Public Health. Dr. Finn is the Translational Chair for ETOP/IBCSG.
  ARCHIVAL MATERIAL   BETA-CATENIN   Cancer Molecular Diagnostics   Cancer/Carcinogenesis   CATENIN COMPLEX   Diagnostic bioimaging   DIAGNOSTIC LABORATORIES   DIGESTIVE TRACTS   DISSECTION   E-CADHERIN   EPITHELIAL-CELLS   FROZEN SECTION   GASTRIC CARCINOMAS   GENE   H4 D10S170   HASHIMOTO THYROIDITIS   HEAD AND NECK CANCER   Imaging Techniques   Lipid metabolism   Lung Cancer   NECK DISSECTION   Obesity   ORAL CAVITY   PAPILLARY THYROID CARCINOMA   Pathology   PATTERNS   Prostate cancer   RATIONALE   RET PROTOONCOGENE   RET/PTC-1   SQUAMOUS-CELL-CARCINOMA   STAGING   STAGING PROCEDURE   TAQMAN RT-PCR   TYROSINE PHOSPHORYLATION
Project Title
 Identifying non-coding RNA repertoires of aggressive Prostate cancer
From
01/01/12
To
30/12/14
Summary
Abstract: Although there has been significant progress in the basic understanding of why prostate cancer (PCa) arises and how it progresses, these advances, unfortunately, have not translated into a cure and have most often have been disappointing with little benefit to men with aggressive PCa. Clinically relevant biomarkers are lacking and simple prognostication in PCa remains elusive outside of the now decades old pathological Gleason scoring system. Our hypothesis, supported by miRNA data from our laboratories, is that non-coding RNA signatures (including known and novel miRNAs) play a key role in aggressive PCa. In addition, cancer stemness is associated with poor prognosis and aggressive PCa. Therefore, we further hypothesize that non-coding RNA expression profiles, particularly miRNA, are linked to stemness in cancer and a clinically aggressive phenotype. In this application, we aim to model stem cell rich PCa and profile biologically aggressive PCa (high Gleason grade) to identify, in hypothesis neutral experiments, non-coding RNAs associated with aggressive and progressive prostate cancer. miRNAs and their isoMirs will be defined in our holoclone stem cell models and high Gleason score tumours, from the biorepository of the Prostate Cancer Research Consortium (PCRC) in Ireland, and compared to founder cells and indolent prostate cancer respectively. Using advanced bioinformatics we will look for stemness and aggression signatures and use these in a smaller focused panel to assess in relation to outcome in richly and meticulously annotated prostate cancer databases from the Physicians Health Study and Health Professionals Follow Up Study. This study will also uniquely identify ncRNA other than miRNA (piRNA, snoRNA, transcribed ultra-conserved regions) and we expect that these will also contribute to the signatures derived. This study will for the first time provide an in depth profile of isoMirs in prostate cancer. We will also integrate existing and newly undertaken gene expression profiles to examine ncRNA in relation to gene expression patterns and pathways with the aim of deriving integrated ncRNA and mRNA profiles in clinically aggressive PCa. Validation will be performed in independent cohorts and in databases of our collaborators in the United States (Harvard School of Public Health). The latter resource allows us to assess outcome in relation to Prostate cancer specific death rather than PSA failure and is annotated for protein pathway, gene expression profiling and clinical data. Aggressive disease in the Harvard datasets is characterized by the presence of metastases or death from PCa. Finally, in a proof of concept study, we will examine the utility of the profiles discovered to monitor disease progression in circulating tumour cells from patients with aggressive metastatic prostate cancer. With the emergence of ncRNA-based therapeutics there is clear translational potential. The ultimate aim is to translate to the clinic non-coding RNA profiles that can be used to inform treatment options for patients with aggressive prostate cancer.
Funding Agency
Prostate Cancer Foundation
Project Type
Personal Fellowship
Project Title
 EXPECT Trial: Evasion of immune editing by circulating tumour cells is an exercise-modifiable mechanism underlying aggressive behaviour in obese men with prostate cancer
From
01/01/2014
To
Summary
1. Abstract 1.1 Background Obesity, known to be associated with a pro-inflammatory, pro-thrombotic humoral milieu, confers a worse prognosis in prostate cancer (PrCa). Circulating tumour cells (CTCs) are identified in the blood in advanced cancer. Their quantitation provides prognostic information. "Cloaking" of CTCs by adherent platelets impedes NK-cell clearance of CTCs from the circulation, enhancing metastatic spread. NK-cell function in blood and in solid organs is quantitatively and qualitatively reduced in obesity. Platelet cloaking may be enhanced in obesity due to the pro-inflammatory, pro-thrombotic state, and may be a mechanism for worse cancer-specific outcomes in this group. Obesity and its biochemical effects may be influenced by lifestyle changes such as exercise. Physical activity reduces levels of systemic inflammatory mediators and so an aerobic exercise intervention may represent an accessible and cost-effective means of ameliorating the pro-inflammatory effects of obesity. 1.2 Objectives To determine whether 1. Platelet cloaking of PrCa CTCs is more prominent in men with obesity than without 2. Regular exercise can improve quality of life (QoL) and ameliorate platelet cloaking 3. The degree of platelet cloaking varies with levels of systemic and primary tumour inflammation and coagulability 4. Expression of an obesity-associated lethality gene signature leads to variation in platelet cloaking 1.3 Setting and Methods This international multicentre prospective study will recruit 200 men with metastatic PrCa, dividing them into exposed and non-exposed groups based on BMI ≥ 25. Participants will be recruited from centres in Dublin (Ireland), Örebro (Sweden) and London (UK), and will be randomized to intervention and comparison groups. Blood samples will be taken at recruitment (T0) and at three (T3) and six months (T6). Project 1: CTCs will be enumerated in the T0 samples. Adherent platelets will be quantified and compared between the exposed and non-exposed groups, and correlated with clinicopathological parameters. Project 2: The intervention group will undertake a regular supervised aerobic exercise programme, whereas the comparison group will not. T3 and T6 blood samples will be assessed for CTC numbers and platelet cloaking. Changes will be compared with the T0 sample and between exposed and non-exposed and intervention and comparison groups. Participants will complete a detailed questionnaire to assess quality of life and other parameters at each visit. Project 3: All blood samples will be assessed for NK-cell number and activation, markers of systemic inflammation, adipokines and serum factors related to platelet activation. The prostate needle core biopsies will be examined microscopically for atrophy and inflammation, by morphology and immunohistochemistry, with particular reference to NK-cells. All variables will be correlated with platelet cloaking. Project 4: NCBs will be assessed for expression of an obesity-associated lethality gene signature (whose genes are known to play a role in obesity or platelet aggregation and coagulation), and correlated with platelet cloaking. 1.4 Impact This study aims to elucidate a potential mechanism by which obesity confers a worse prognosis in PrCa, two increasingly prevalent diseases in the western world. We hope to show that a low-cost, accessible intervention can improve QoL and potentially ameliorate the effects of obesity through alterations in the systemic adipokine and inflammatory mediator profile.
Funding Agency
World Cancer Research Fund
Project Type
Trial
Project Title
 Discovery and Clinical Implementation of Novel Predictive Biomarkers for Enzalutamide therapy
From
01/01/2014
To
Summary
Scientific Abstract: Building on funding secured from Bayer and Astellas to perform a clinical trial (Phase II Study of Radium-223 in Combination with Enzalutamide in progressive Osseous-Predominant Metastatic CRPC) this translational project will discover new mutations in the Androgen Receptor and validate existing candidates in the Androgen Receptor Ligand binding domain (W741C and F876L) for response to Enzalutamide (ENZ) using serial, liquid biopsies, tissue biopsies and rapid autopsy tissues. Critically we will develop these assays for accurate stratification of patients and for use in routine blood samples collected from patients before and during Enzalutamide therapy using cell free circulating DNA and circulating tumour cells allied to massively parallel next generation sequencing.
Funding Agency
Irish Cancer Society
Programme
Movember Transformative iPROSPECT

Details Date From Date To
Fellow of the Royal College of Pathologists 2005 Current
Ciara S. McNevin, Anna Keogh, Mutaz Mohammed Nur, Brianán McGovern, Julie McFadden, Anne"Marie Baird, Karen A. Cadoo, Sarah Mc Carron, Cathal Ó"Brien, Martin P. Barr, Steven G. Gray, Orla Sheils, Lesley Ann Sutton, Sinéad Flanagan, Lorelei A. Mucci, Konrad H. Stopsack, Stephen P. Finn, Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large Prospective Cohort, Clinical Cancer Research, 2025, Journal Article, PUBLISHED  DOI
Martina Haberecker, Jan H. Rüschoff, Charitini Andriakopoulou, Steven G. Gray, Kristiaan Nackaerts, Marc de Perrot, Luka Br"i", Ernest Nadal, Sotirios Tsimpoukis, Luca Ampollini, Joachim G.J.V. Aerts, Michaela B. Kirschner, Kim Monkhorst, Birgit Weynand, Fatemeh Bavaghar-Zaeimi, Miroslav Samaržija, Roger Llatjos, Stephen P. Finn, Enrico Maria Silini, Jan H. von der Thüsen, Patrick Vagenknecht, Zoi Tsourti, Keith M. Kerr, Roswitha Kammler, Solange Peters, Paul Baas, Isabelle Opitz, Rolf A. Stahel, Alessandra Curioni"Fontecedro, Rolf A. Stahel, Anita Hiltbrunner, Rosita Kammler, Patrick Vagenknecht, Miriam Christoffel, Barbara Ruepp, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Androniki Stavrou, Jan H. Rüschoff, Martina Haberecker, Susanne Dettwiler, Fabiola Prutek, Christiane Mittmann, Isabelle Opitz, Paul Baas, Isabelle Opitz, Bart Vrugt, Martina Friess, Alessandra Matter, Chloé Spichiger-Häusermann, Michaela B. Kirschner, Paul Baas, Kim Monkhorst, Kristiaan Nackaerts, Eric Verbeken, Birgit Weynand, Liesbet M. Peeters, Luca Ampollini, Marcello Tiseo, Enrico Maria Silini, Letizia Gnetti, Marc de Perrot, Fatemeh B. Zaeimi, Luka Br"i", Miroslav Samaržija, Sven Seiwerth, Marko Jakopovi", Ernest Nadal, Enriqueta Felip, Roger Llatjós, Susana Lorente, Konstantinos Syrigos, Ioannis Vamvakaris, Sotirios Tsimpoukis, Paraskevi Boura, Steven G. Gray, Stephen P. Finn, Mutaz Mohammed Nur, Anne"Marie Baird, Nesa Marti, Sinéad Cuffe, Kathy Gately, Joachim G.J.V. Aerts, Jan H. von der Thüsen, Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project, JCO Precision Oncology, (9), 2025, Journal Article, PUBLISHED  DOI
Peters S, Loi S, André F, Chandarlapaty S, Felip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, Stahel RA., Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation., Annals of oncology : official journal of the European Society for Medical Oncology, 35, (7), 2024, p607-629 , Journal Article, PUBLISHED  DOI
Speel EM, Dafni U, Thunnissen E, Hendrik Rüschoff J, O'Brien C, Kowalski J, Kerr KM, Bubendorf L, Sansano I, Joseph L, Kriegsmann M, Navarro A, Monkhorst K, Bille Madsen L, Hernandez Losa J, Biernat W, Stenzinger A, Rüland A, Hillen LM, Marti N, Molina-Vila MA, Dellaporta T, Kammler R, Peters S, Stahel RA, Finn SP, Radonic T, Lungscape Consortium (see Appendix)., ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project., Lung cancer (Amsterdam, Netherlands), 194, 2024, p107860 , Journal Article, PUBLISHED  DOI
M Saini, Volga, Oner, Ezgi, Ward, Mark P., Hurley, Sinead, Henderson, Brian David, Lewis, Faye, Finn, Stephen P., Fitzmaurice, Gerard J., O'Leary, John J., O'Toole, Sharon, O'Driscoll, Lorraine, Gately, Kathy, A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer, Molecular Oncology, 2024, Journal Article, PUBLISHED  DOI
Vaselkiv JB, Shui IM, Grob ST, Ericsson CI, Giovannucci I, Peng C, Finn SP, Mucci LA, Penney KL, Stopsack KH., Intratumoral vitamin D signaling and lethal prostate cancer., Carcinogenesis, 45, (10), 2024, p735-744 , Journal Article, PUBLISHED  DOI
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA, ETOP 10-16 BOOSTER Collaborators., ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial., Clinical cancer research : an official journal of the American Association for Cancer Research, 30, (22), 2024, p5180-5191 , Journal Article, PUBLISHED  DOI
Huang L, Winter SJ, Olsson LT, Hamilton AM, Halliday SR, Kirk EL, Farnan L, Gerstel A, Craig SG, Finn SP, LaBonte Wilson M, Jain S, Troester MA, Butler EN, Bensen JT, Wobker SE, Allott EH., Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression., Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 33, (12), 2024, p1623-1632 , Journal Article, PUBLISHED  DOI
Murchan, P. and Baird, A.-M. and Ã" Broin, P. and Sheils, O. and Finn, S.P., Surrogate Biomarker Prediction from Whole-Slide Images for Evaluating Overall Survival in Lung Adenocarcinoma, Diagnostics, 14, (5), 2024, Notes: [cited By 0], Journal Article, PUBLISHED  DOI
Barry Digby, Stephen P. Finn, Pilib Ó Broin, Computational approaches and challenges in the analysis of circRNA data, BMC Genomics, 25, (1), 2024, Journal Article, PUBLISHED  DOI
  

Page 1 of 30
Duncan HF, Endodontics, Faculty of Dentistry's Postgraduate Intensive Programme, RCSI, 6th September, 2014, RCSI Dental Faculty, Invited Talk, PRESENTED